Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.66 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TNKS | O95271 | 3/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31607797 | 1.00 | CRBN (0.66) | CRBNDDB1MEN1KMT2ATNKS | |
| SCHEMBL6179230 | 0.85 | KMT2A (0.50) | CRBNDDB1MEN1KMT2AALOX5 | |
| SCHEMBL31607792 | 0.84 | CRBN (0.63) | CRBNDDB1MEN1KMT2ATNKS | |
| SCHEMBL8631856 | 0.84 | KMT2A (0.66) | CRBNDDB1MEN1KMT2AMGLL | |
| SCHEMBL30015009 | 0.79 | CRBN (0.66) | CRBNDDB1TNKSTNKS2ALOX5 | |
| SCHEMBL31040970 | 0.79 | CRBN (1.00) | CRBNDDB1MEN1KMT2ATNKS | |
| SCHEMBL31393524 | 0.79 | CRBN (0.66) | CRBNDDB1TNKSTNKS2MGLL | |
| SCHEMBL31040941 | 0.79 | CRBN (0.66) | CRBNDDB1TNKSTNKS2 | |
| SCHEMBL24319707 | 0.79 | CRBN (0.57) | CRBNDDB1MEN1KMT2ATNKS | |
| SCHEMBL31607784 | 0.79 | CRBN (0.60) | CRBNDDB1MEN1KMT2ATNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393922-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| EP-4194457-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022223034-A1 | SOS1 DEGRADATION AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海领泰生物医药科技有限公司 | 2022-10-27 | — | — | WO | disclosed |
| WO-2022223033-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海领泰生物医药科技有限公司 | 2022-10-27 | — | — | WO | disclosed |
| WO-2022223039-A1 | SOS1 DEGRADER, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海领泰生物医药科技有限公司 | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | CRBN 221/4885DDB1 1973/4885MEN1 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.